Related Experiment Video
Updated: May 16, 2026
Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
Published on: September 27, 2024
Association between blood eosinophil count and in-hospital mortality among systemic corticosteroids-treated patients
1Department of Internal Medicine, Division of Pulmonary Medicine, Institute of Integrated Traditional and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
Background:
Systemic corticosteroids (SCS) are commonly used for acute exacerbation of COPD (AECOPD), but their effect in patients with COPD-bronchiectasis overlap remains unclear. Whether admission blood eosinophil count (BEC) modifies clinical outcomes in this population is not well-defined.
Methods:
This single-center retrospective cohort study included hospitalized AECOPD patients with radiologically confirmed bronchiectasis (2011-2020). Patients were stratified based on admission BEC. The independent associations of BEC with in-hospital mortality and other outcomes in SCS-treated COPD-bronchiectasis overlap patients were rigorously assessed using multivariable logistic regression and propensity score matching analyses.
Results:
Among 9,699 AECOPD patients, 1,421 (14.65%) had bronchiectasis. SCS use was more common in patients with greater disease severity and lower baseline BEC. In the overall overlap cohort, SCS was not independently associated with mortality after adjustment. However, BEC significantly modified this relationship. In patients with BEC <300 cells/μL, SCS use was associated with increased in-hospital mortality (adjusted OR 2.05, P = 0.038), with the highest risk observed in the very low BEC subgroup (<100 cells/μL) (adjusted OR 8.68, P = 0.015), particularly among the elderly (≥70 years) and those with severe radiological bronchiectasis. Conversely, for patients with high BEC level (≥300 cells/μL), SCS use was not linked to increased mortality and was associated with reduced antibiotic treatment.
Conclusion:
In this study, BEC appeared to modify the association between SCS and clinical outcomes in hospitalized COPD-bronchiectasis overlap patients. Observationally, SCS was associated with increased mortality in patients with low BEC, especially among the elderly and those with severe bronchiectasis, whereas no such risk was observed in patients with high BEC. These findings are hypothesis-generating and highlight the potential of BEC to inform personalized treatment strategies. However, they require rigorous prospective validation in randomized controlled trials before any clinical implementation can be considered.
Related Concept Videos
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:24Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...